Cost regulators have made what seems to be a significant U-turn over Takeda’s Adcetris, with the likelihood that it will be possible for Hodgkin lymphoma to gain routines NHS access to the drug.
Adcetris (brentuximab vedotin) has already been cleared in Europe to treat CD30-positive Hodgkin’s.
But Nice had rejected the drug due to cost-effectiveness concerns.
The healthcare body also cited what it considered to be uncertainties in evidence related to the drug.
Yet Nice has now reversed... Readmore
National Institute for Health and Care Excellence experts have supported the use of Janssen’s biologic Stelara.
The substance is utilised in order to treat adult patients with Crohn’s disease, with Stelara able to deal with some of the more severe cases.
A Final Appraisal Determination has already been issued recommending the drug in line with its licensed indication.
Stelara will be used when patients fail to respond to conventional therapy or an anti-TNF-alpha therapy.
Crohn's is known... Readmore
Representatives of the pharmaceutical industry have collectively suggested that many firms could withdraw from Britain and delay major drug launches unless the NHS receives a funding boost.
The manifesto of the Association of the British Pharmaceutical Industry (ABPI) suggests that health spending should be boosted to 11% of GDP from 9.9%.
This would amount to approximately £20 billion annually.
Lisa Anson, the new president of the ABPI and country president of AstraZeneca, suggested that... Readmore
Wales is to receive the game-changing Prep HIV drug, as part of a three-year trial.
This is despite the fact that the All Wales Medicines Strategy Group (AWMSG) has previously advised the Welsh government to oppose the funding of Prep due to its lack of cost-effectiveness.
AWMSG had stated previously that there were "several uncertainties and limitations" in the economic model provided by the manufacturer of the drug.
But Health Secretary Vaughan Gething has announced that during the research... Readmore
New clinical data indicates that a major form of medication has a massive impact on a prominent virus.
AbbVie’s late-stage information demonstrates that the ribavirin-free hepatitis C therapy glecaprevir/pibrentasvir has achieved high cure rates across the majority of patients infected with the virus.
Glecaprevir/pibrentasvir is a once-daily regimen that combines two distinct antiviral agents.
Both the NS3/4A protease inhibitor glecaprevir (300mg) and NS5A inhibitor pibrentasvir (120mg)... Readmore
The National Institute for Health and Care Excellence (NICE) has backed the utilisation of Novartis’ Cosentyx (secukinumab) in adults with active and progressive psoriatic arthritis.
Progressive psoriatic arthritis is an inflammatory disease that affects joints and connective-tissue, impacting over 117,000 people in Britain.
It can strike at any point during a person's lifetime, but the most affected the group are those aged between 40 and 50.
The watchdog is already recommending the use of Cosentyx... Readmore
The pharmaceutical company Allergan has announced a major collaboration with Novartis.
This new arrangement between the pharma giants will see them test a new combination therapy approach for non-alcoholic steatohepatitis.
Non-alcoholic steatohepatitis is a progressive form of non-alcoholic fatty liver disease that is considered to be the fastest growing cause of liver cancer and liver transplant in the United States.
In order to achieve this, Allergan is expanding its research and development... Readmore
Onzima Ventures has announced the conditional acquisition of the remaining 51% of the issued shares of N4 Pharma Limited, effectively taking over the firm.
Consideration for the acquisition will be satisfied by the issue of 4,510,800 New Ordinary Shares and 4,591,400 Deferred Consideration Shares.
The Company has also conditionally raised £1.5 million (gross) by way of a placing of 21,428,571 New Ordinary Shares at 7p per share .
This will be utilised in order to fund development of additional... Readmore
Polyphor Ltd has the completion of a CHF40 million private placement.
Exisiting Polyphor investors contributed to 98% of the financing.
Polyphor is a clinical stage, privately held Swiss specialty pharma company focused on the development of macrocycle drugs addressing antibiotic resistance and respiratory diseases.
The proceeds will be used to finance the Pharma business unit, and particularly the pivotal registration programme of the antibiotic Murepavadin (POL7080) against... Readmore
A breast cancer drug that has previously been withdrawn in England has been made available via the NHS in Scotland.
This is the second blow for medical prescriptions south of the border, after NHS Scotland agreed to fund PrEP for HIV sufferers.
Kadcyla is used to treat the form of breast cancer known as HER2 positive.
The Scottish Medicines Consortium (SMC) suggest that making the major available to patients in Scotland will enable them to spend "more time with their families and in some... Readmore
PrEP is to be made available in Scotland, with AIDS campaigners suggesting that the English authorities should now follow suit.
Two major court rulings have previously forbade this process, but it is hoped that the authorities will now make the medicine available for HIV sufferers in other British nations.
The Scottish Medicines Consortium (SMC) decided to make PrEP free on the NHS to those who could require the drug.
Access to the medication could begin within the next few weeks.
A new study widely reported in the British media suggests that taking antibiotics for in excess of two weeks can massively increase the risk of bowel cancer developing.
However, reports on the matter have been rather misleading, as the study in question did not in fact assess the level of bowel cancer.
What it did discover is an increased risk of bowel polyps for women who took antibiotics for two months or more.
The study was carried out by researchers from Harvard Medical School, Harvard... Readmore